Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments. — CFSMEATLAS
Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments.
Almenar-Pérez, Eloy, Sánchez-Fito, Teresa, Ovejero, Tamara et al. · Pharmaceutics · 2019 · DOI
Quick Summary
This study looked at how medicines commonly taken by fibromyalgia and ME/CFS patients might interfere with blood tests that could help diagnose these conditions. The researchers found that many prescription drugs can affect small molecules in the body called microRNAs, which are being studied as potential diagnostic markers. This means that when researchers try to identify disease-specific biomarkers, they may be picking up drug effects instead of actual disease signatures.
Why It Matters
This research highlights a critical and previously underappreciated barrier to developing reliable diagnostic tests for ME/CFS: the confounding effects of medications that most patients take. Understanding how drugs mask true disease biomarkers could accelerate the discovery of valid diagnostic markers and enable more personalized treatment approaches for ME/CFS patients. It also raises awareness that miRNA profiles could eventually help doctors choose safer, more effective medications tailored to individual patients.
Observed Findings
Multiple commonly prescribed medications used by FM and ME/CFS patients were found to alter miRNA expression patterns relevant to disease diagnosis.
Drug-induced miRNA changes could mask or mimic disease-associated differential miRNA expression.
FM and ME/CFS miRNomes may influence treatment response and toxicity risk for various conditions, including cancer therapies.
ME/CFS patients show elevated lymphoma incidence, which may be affected by disease miRNA profiles.
Inferred Conclusions
Polypharmacy represents a significant confounding variable in FM and ME/CFS biomarker discovery that must be systematically controlled for in future studies.
Disease miRNomes could support pharmacogenomic and pharmacoepigenomic profiling to advance personalized and precision medicine in these patient populations.
Integrating miRNA profiling with medication assessment may be necessary for developing clinically valid diagnostic tests.
Remaining Questions
Which specific drug-miRNA interactions have the largest impact on biomarker detection sensitivity and specificity in ME/CFS patients?
Can miRNA profiles reliably predict drug toxicity or treatment response in ME/CFS patients across different medication classes?
What This Study Does Not Prove
This study does not prove that any specific drug definitively causes false biomarker results in individual ME/CFS patients, nor does it demonstrate that validated diagnostic biomarkers will become available once drug effects are controlled for. It is a literature review identifying potential interactions rather than an experimental study measuring actual biomarker changes in patients. The findings are associational and do not establish the clinical magnitude or reversibility of drug-induced miRNA alterations.